CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
Introduction: There are still no effective diagnostic and prognostic biomarkers in pancreatic ductal adenocarcinoma (PDAC). The differentiation between PDAC and chronic pancreatitis (CP) is often challenging. The inflammatory mass in the course of CP causes diagnostic difficulties in differentiating...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/12/4050 |
| _version_ | 1797594126146863104 |
|---|---|
| author | Barbara Wlodarczyk Lukasz Durko Przemyslaw Wlodarczyk Renata Talar-Wojnarowska Ewa Malecka-Wojciesko |
| author_facet | Barbara Wlodarczyk Lukasz Durko Przemyslaw Wlodarczyk Renata Talar-Wojnarowska Ewa Malecka-Wojciesko |
| author_sort | Barbara Wlodarczyk |
| collection | DOAJ |
| description | Introduction: There are still no effective diagnostic and prognostic biomarkers in pancreatic ductal adenocarcinoma (PDAC). The differentiation between PDAC and chronic pancreatitis (CP) is often challenging. The inflammatory mass in the course of CP causes diagnostic difficulties in differentiating them from neoplastic lesions and, thus, delays the initiation of radical treatment. Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 2 (IGFBP-2) form a network involved in PDAC development. The role of IGFs in promoting pancreatic cancer cell proliferation, survival, and migration is well established, and their ability to stimulate tumor growth and metastasis is well documented. The aim of the study was to evaluate the usability of IGF-1, IGFBP-2, and IGF-1/IGFBP-2 ratio in PDAC and CP differentiation. Material and methods: The study included 137 patients: 89 patients with PDAC and 48 patients with CP. All subjects were tested for the levels of IGF-1 and IGFBP-2 using the ELISA method (Corgenix UK Ltd. R&D Systems), along with the level of CA 19-9 in serum. Additionally, the IGF-1/IGFBP-2 ratio was calculated. Further analyses used logit and probit models with varying determinants in order to discern between PDAC and CP patients. The models served as a basis for AUROC calculation. Results: The mean IGF-1 serum level was equal to 52.12 ± 33.13 ng/mL in PDAC vs. 74.23 ± 48.98 ng/mL in CP (<i>p</i> = 0.0053). The mean level of IGFBP-2 was equal to 305.95 ± 194.58 ng/mL in PDAC vs. 485.43 ± 299 ng/mL in CP (<i>p</i> = 0.0002). The mean CA 19-9 serum concentration was 434.95 ± 419.98 U/mL in PDAC vs. 78.07 ± 182.36 U/mL in CP (<i>p</i> = 0.0000). The mean IGF-1/IGFBP-2 ratio was 0.213 ± 0.14 in PDAC vs. 0.277 ± 0.33 in CP (<i>p</i> = 0.1914). The diagnostic usefulness of indicators for the purpose of PDAC and CP differentiation was assessed by means of AUROC comparison. The AUROCs of IGF-1, IGFBP-2, and IGF-1/IGFBP-2 ratio ranged below 0.7, being lower than the AUROC of CA 19-9 (0.7953; 0.719 within 95% CI). Together, the CA 19-9 and IGFBP-2 AUROCs also ranged below 0.8. When age was included, the AUROC increased to 0.8632, and its 95% confidence interval held above the 0.8 limit. The sensitivity of the used markers was not correlated to the stage of pancreatic PDAC. Conclusions: The presented results indicate that CA 19-9 is a marker demonstrating high potential for PDAC and CP differentiation. The inclusion of additional variables into the model, such as the serum level of IGF-1 or IGFBP-2, slightly increased the sensitivity in differentiating CP from PDAC. The IGF-1/IGFBP-2 ratio turned out to be a good marker of pancreatic diseases, but insufficient for the purpose of CP and PDAC differentiation. |
| first_indexed | 2024-03-11T02:18:08Z |
| format | Article |
| id | doaj.art-270eec6118ee407bba4932f8e27bd321 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-11T02:18:08Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-270eec6118ee407bba4932f8e27bd3212023-11-18T11:00:17ZengMDPI AGJournal of Clinical Medicine2077-03832023-06-011212405010.3390/jcm12124050CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) DifferentiationBarbara Wlodarczyk0Lukasz Durko1Przemyslaw Wlodarczyk2Renata Talar-Wojnarowska3Ewa Malecka-Wojciesko4Department of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, PolandDepartment of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, PolandFaculty of Economics and Sociology, University of Lodz, 90-419 Lodz, PolandDepartment of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, PolandDepartment of Digestive Tract Diseases, Medical University of Lodz, 90-419 Lodz, PolandIntroduction: There are still no effective diagnostic and prognostic biomarkers in pancreatic ductal adenocarcinoma (PDAC). The differentiation between PDAC and chronic pancreatitis (CP) is often challenging. The inflammatory mass in the course of CP causes diagnostic difficulties in differentiating them from neoplastic lesions and, thus, delays the initiation of radical treatment. Insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 2 (IGFBP-2) form a network involved in PDAC development. The role of IGFs in promoting pancreatic cancer cell proliferation, survival, and migration is well established, and their ability to stimulate tumor growth and metastasis is well documented. The aim of the study was to evaluate the usability of IGF-1, IGFBP-2, and IGF-1/IGFBP-2 ratio in PDAC and CP differentiation. Material and methods: The study included 137 patients: 89 patients with PDAC and 48 patients with CP. All subjects were tested for the levels of IGF-1 and IGFBP-2 using the ELISA method (Corgenix UK Ltd. R&D Systems), along with the level of CA 19-9 in serum. Additionally, the IGF-1/IGFBP-2 ratio was calculated. Further analyses used logit and probit models with varying determinants in order to discern between PDAC and CP patients. The models served as a basis for AUROC calculation. Results: The mean IGF-1 serum level was equal to 52.12 ± 33.13 ng/mL in PDAC vs. 74.23 ± 48.98 ng/mL in CP (<i>p</i> = 0.0053). The mean level of IGFBP-2 was equal to 305.95 ± 194.58 ng/mL in PDAC vs. 485.43 ± 299 ng/mL in CP (<i>p</i> = 0.0002). The mean CA 19-9 serum concentration was 434.95 ± 419.98 U/mL in PDAC vs. 78.07 ± 182.36 U/mL in CP (<i>p</i> = 0.0000). The mean IGF-1/IGFBP-2 ratio was 0.213 ± 0.14 in PDAC vs. 0.277 ± 0.33 in CP (<i>p</i> = 0.1914). The diagnostic usefulness of indicators for the purpose of PDAC and CP differentiation was assessed by means of AUROC comparison. The AUROCs of IGF-1, IGFBP-2, and IGF-1/IGFBP-2 ratio ranged below 0.7, being lower than the AUROC of CA 19-9 (0.7953; 0.719 within 95% CI). Together, the CA 19-9 and IGFBP-2 AUROCs also ranged below 0.8. When age was included, the AUROC increased to 0.8632, and its 95% confidence interval held above the 0.8 limit. The sensitivity of the used markers was not correlated to the stage of pancreatic PDAC. Conclusions: The presented results indicate that CA 19-9 is a marker demonstrating high potential for PDAC and CP differentiation. The inclusion of additional variables into the model, such as the serum level of IGF-1 or IGFBP-2, slightly increased the sensitivity in differentiating CP from PDAC. The IGF-1/IGFBP-2 ratio turned out to be a good marker of pancreatic diseases, but insufficient for the purpose of CP and PDAC differentiation.https://www.mdpi.com/2077-0383/12/12/4050pancreatic cancerchronic pancreatitisinsulin-like growth factor 1insulin-like growth factor-binding protein 2 |
| spellingShingle | Barbara Wlodarczyk Lukasz Durko Przemyslaw Wlodarczyk Renata Talar-Wojnarowska Ewa Malecka-Wojciesko CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation Journal of Clinical Medicine pancreatic cancer chronic pancreatitis insulin-like growth factor 1 insulin-like growth factor-binding protein 2 |
| title | CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation |
| title_full | CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation |
| title_fullStr | CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation |
| title_full_unstemmed | CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation |
| title_short | CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation |
| title_sort | ca 19 9 but not igf 1 igfbp 2 is a useful biomarker for pancreatic ductal adenocarcinoma pdac and chronic pancreatitis cp differentiation |
| topic | pancreatic cancer chronic pancreatitis insulin-like growth factor 1 insulin-like growth factor-binding protein 2 |
| url | https://www.mdpi.com/2077-0383/12/12/4050 |
| work_keys_str_mv | AT barbarawlodarczyk ca199butnotigf1igfbp2isausefulbiomarkerforpancreaticductaladenocarcinomapdacandchronicpancreatitiscpdifferentiation AT lukaszdurko ca199butnotigf1igfbp2isausefulbiomarkerforpancreaticductaladenocarcinomapdacandchronicpancreatitiscpdifferentiation AT przemyslawwlodarczyk ca199butnotigf1igfbp2isausefulbiomarkerforpancreaticductaladenocarcinomapdacandchronicpancreatitiscpdifferentiation AT renatatalarwojnarowska ca199butnotigf1igfbp2isausefulbiomarkerforpancreaticductaladenocarcinomapdacandchronicpancreatitiscpdifferentiation AT ewamaleckawojciesko ca199butnotigf1igfbp2isausefulbiomarkerforpancreaticductaladenocarcinomapdacandchronicpancreatitiscpdifferentiation |